NCT07123181
Oregano and Basil Leaves and Coronary Artery Disease
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 2 months later.
See at-risk trials from Shahid Beheshti University of Medical Sciences
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 6 words
- Primary completion pushed from Sep 28, 2026 to Dec 21, 2026
- Study completion pushed from Oct 22, 2026 to Jan 30, 2027
- Secondary endpoints: details revised at 1 of 3 entries
- Notable Primary completion date: Mar 17, 2026 to Sep 28, 2026
- Study completion date: Jun 2, 2026 to Oct 22, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Plasma inflammatory biomarkers
Timeframe: At the beginning of the study and two months later
Plasma lipids
Timeframe: At the beginning of the study and two months later
Secondary (3)
Plasma malondialdehyde
Urinary total polyphenols
Plasma PCSK9 and PAI-1 levels
Arms and interventions
ControlOther
Standard medical treatment
Higher polyphenol intake by consumption of oregano and basilExperimental
Daily consumption of oregano and basil leaves along with standard medical treatment
Other: Control (Standard treatment), Higher polyphenol intake by consumption of oregano and basil
Sites
1 site in 1 country
- Imam Husain hospitalTehran, Tehran Province, Iran